Whalesbook
Aurobindo Pharma is set to repurchase up to 54.23 lakh shares for ₹800 crore, at ₹1,475 per share, through a tender offer. The buyback period runs from April 23 to April 29, 2026, with shareholders of record on April 17, 2026, eligible to participate. The offer price of ₹1,475 is notably higher than the stock's recent trading price, which was around ₹1,387.05 on April 21, 2026. This offers shareholders a chance to sell their shares at a premium and could help support the stock price during the tender period.
The company's stock has shown resilience, reaching a 52-week high close to ₹1,401 on April 21, 2026. It has also outperformed the broader Sensex index over the last year. This latest buyback continues a pattern of returning capital to shareholders; Aurobindo Pharma conducted a similar ₹750 crore repurchase in August 2024 at ₹1,460 per share. Management's decision to buy back shares suggests they believe the stock is undervalued.
The pharmaceutical sector in India presents a mixed picture. While international markets, especially the US, face challenges from patent expirations on key drugs, the domestic market is growing strongly. For the fiscal year ending March 2026, India's pharmaceutical market saw significant value growth, with the final quarter showing the best performance in over a year, boosted by increased volumes and demand for chronic therapies like cardiac and anti-diabetic medicines.
Aurobindo Pharma's Price-to-Earnings (P/E) ratio of about 22.8x is lower than the industry average of roughly 28x. Competitors like Cipla and Lupin have similar P/E ratios, while Natco Pharma and Zydus Lifesciences trade at lower multiples. This valuation makes Aurobindo Pharma appear attractive compared to its peers, particularly given its strength in the domestic market.
Analysts generally hold a positive view, with a consensus 'Buy' rating. The average 12-month price target is around ₹1,380, suggesting limited immediate upside from current trading prices but indicating confidence in the company's long-term future.
However, challenges remain. Aurobindo Pharma's performance is still linked to its US formulations business, which faces slow growth, pricing pressures, and generic competition. While the buyback is financially sound, its size is modest, representing about 0.93% of the company's total equity. Past buybacks, including one in July 2024, have consistently used the tender offer method, showing a steady approach to capital return. The company must also navigate changing regulations in key markets and risks in expanding its product offerings or geographic reach. Additionally, while its P/E ratio is below the industry average, its PEG ratio of 2.36 suggests it might be overvalued relative to its earnings growth rate.
Looking ahead, analysts have high price targets from some firms, with JM Financial suggesting ₹1,610 and HDFC Securities ₹1,755, indicating potential for a significant re-rating. Aurobindo Pharma's focus on growing its domestic chronic therapy business and managing capital wisely through buybacks positions it well to capitalize on India's increasing healthcare demand, while still navigating complex international markets.